Company Filing History:
Years Active: 2007
Title: Franck Touraud: Innovator in Pharmaceutical Vector Technology
Introduction
Franck Touraud is a notable inventor based in Lyons, France. He has made significant contributions to the field of pharmaceutical technology, particularly in the development of innovative vector systems for drug delivery.
Latest Patents
Touraud holds a patent for a "Colloidal suspension of submicronic particles as vectors for active principles and method for preparing same." This invention involves a suspension of vector particles based on polyamino acids, which have a mean hydrodynamic diameter between 30 and 120 nm. The insulin load factor ranges from 5 to 25% of the associated insulin volume relative to the polyamino acid volume forming the vector particles. The polyamino acids utilized are double-block polymers containing both hydrophilic and hydrophobic monomers. The preparation method includes copolymerizing N-carboxy anhydrides of hydrophobic monomers and precursors of hydrophilic monomers, using N-methyl pyrrolidone and methanol. The copolymer can be neutralized, dialyzed, concentrated, and dried to produce a solid powder, which can then be suspended in a liquid to create the colloidal suspension. This technology allows for the association of active principles such as insulin or vaccines with the carrier particles, leading to the development of specialized pharmaceutical products. Touraud has 1 patent to his name.
Career Highlights
Franck Touraud is associated with Flamel Technologies, a company known for its innovative approaches in drug delivery systems. His work has been pivotal in advancing the capabilities of pharmaceutical formulations.
Collaborations
Touraud collaborates with Nathan J Bryson, contributing to the development of cutting-edge technologies in the pharmaceutical sector.
Conclusion
Franck Touraud's innovative work in the field of pharmaceutical vector technology exemplifies the impact of scientific research on drug delivery systems. His contributions continue to shape the future of pharmaceutical products and therapies.